Sifan Lu, Eileen Rakovitch, Breffni Hannon, Camilla Zimmermann, Kavita V Dharmarajan, Michael Yan, John R De Almeida, Christopher M K L Yao, Erin F Gillespie, Fumiko Chino, Divya Yerramilli, Ethan Goonaratne, Fadwa Abdel-Rahman, Hiba Othman, Sara Mheid, Chiaojung Jillian Tsai
{"title":"姑息治疗是转移性癌症患者住院期间高价值和节约成本护理的组成部分。","authors":"Sifan Lu, Eileen Rakovitch, Breffni Hannon, Camilla Zimmermann, Kavita V Dharmarajan, Michael Yan, John R De Almeida, Christopher M K L Yao, Erin F Gillespie, Fumiko Chino, Divya Yerramilli, Ethan Goonaratne, Fadwa Abdel-Rahman, Hiba Othman, Sara Mheid, Chiaojung Jillian Tsai","doi":"10.1200/OP.23.00576","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Randomized controlled trials have demonstrated that palliative care (PC) can improve quality of life and survival for outpatients with advanced cancer, but there are limited population-based data on the value of inpatient PC. We assessed PC as a component of high-value care among a nationally representative sample of inpatients with metastatic cancer and identified hospitalization characteristics significantly associated with high costs.</p><p><strong>Methods: </strong>Hospitalizations of patients 18 years and older with a primary diagnosis of metastatic cancer from the National Inpatient Sample from 2010 to 2019 were analyzed. We used multivariable mixed-effects logistic regression to assess medical services, patient demographics, and hospital characteristics associated with higher charges billed to insurance and hospital costs. Generalized linear mixed-effects models were used to determine cost savings associated with provision of PC.</p><p><strong>Results: </strong>Among 397,691 hospitalizations from 2010 to 2019, the median charge per admission increased by 24.9%, from $44,904 in US dollars (USD) to $56,098 USD, whereas the median hospital cost remained stable at $14,300 USD. Receipt of inpatient PC was associated with significantly lower charges (odds ratio [OR], 0.62 [95% CI, 0.61 to 0.64]; <i>P</i> < .001) and costs (OR, 0.59 [95% CI, 0.58 to 0.61]; <i>P</i> < .001). Factors associated with high charges were receipt of invasive medical ventilation (<i>P</i> < .001) or systemic therapy (<i>P</i> < .001), Hispanic patients (<i>P</i> < .001), young age (18-49 years, <i>P</i> < .001), and for-profit hospitals (<i>P</i> < .001). PC provision was associated with a $1,310 USD (-13.6%, <i>P</i> < .001) reduction in costs per hospitalization compared with no PC, independent of the receipt of invasive care and age.</p><p><strong>Conclusion: </strong>Inpatient PC is associated with reduced hospital costs for patients with metastatic cancer, irrespective of age and receipt of aggressive interventions. Integration of inpatient PC may de-escalate costs incurred through low-value inpatient interventions.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"252-260"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Palliative Care as a Component of High-Value and Cost-Saving Care During Hospitalization for Metastatic Cancer.\",\"authors\":\"Sifan Lu, Eileen Rakovitch, Breffni Hannon, Camilla Zimmermann, Kavita V Dharmarajan, Michael Yan, John R De Almeida, Christopher M K L Yao, Erin F Gillespie, Fumiko Chino, Divya Yerramilli, Ethan Goonaratne, Fadwa Abdel-Rahman, Hiba Othman, Sara Mheid, Chiaojung Jillian Tsai\",\"doi\":\"10.1200/OP.23.00576\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Randomized controlled trials have demonstrated that palliative care (PC) can improve quality of life and survival for outpatients with advanced cancer, but there are limited population-based data on the value of inpatient PC. We assessed PC as a component of high-value care among a nationally representative sample of inpatients with metastatic cancer and identified hospitalization characteristics significantly associated with high costs.</p><p><strong>Methods: </strong>Hospitalizations of patients 18 years and older with a primary diagnosis of metastatic cancer from the National Inpatient Sample from 2010 to 2019 were analyzed. We used multivariable mixed-effects logistic regression to assess medical services, patient demographics, and hospital characteristics associated with higher charges billed to insurance and hospital costs. Generalized linear mixed-effects models were used to determine cost savings associated with provision of PC.</p><p><strong>Results: </strong>Among 397,691 hospitalizations from 2010 to 2019, the median charge per admission increased by 24.9%, from $44,904 in US dollars (USD) to $56,098 USD, whereas the median hospital cost remained stable at $14,300 USD. Receipt of inpatient PC was associated with significantly lower charges (odds ratio [OR], 0.62 [95% CI, 0.61 to 0.64]; <i>P</i> < .001) and costs (OR, 0.59 [95% CI, 0.58 to 0.61]; <i>P</i> < .001). Factors associated with high charges were receipt of invasive medical ventilation (<i>P</i> < .001) or systemic therapy (<i>P</i> < .001), Hispanic patients (<i>P</i> < .001), young age (18-49 years, <i>P</i> < .001), and for-profit hospitals (<i>P</i> < .001). PC provision was associated with a $1,310 USD (-13.6%, <i>P</i> < .001) reduction in costs per hospitalization compared with no PC, independent of the receipt of invasive care and age.</p><p><strong>Conclusion: </strong>Inpatient PC is associated with reduced hospital costs for patients with metastatic cancer, irrespective of age and receipt of aggressive interventions. Integration of inpatient PC may de-escalate costs incurred through low-value inpatient interventions.</p>\",\"PeriodicalId\":14612,\"journal\":{\"name\":\"JCO oncology practice\",\"volume\":\" \",\"pages\":\"252-260\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO oncology practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/OP.23.00576\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP.23.00576","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Palliative Care as a Component of High-Value and Cost-Saving Care During Hospitalization for Metastatic Cancer.
Purpose: Randomized controlled trials have demonstrated that palliative care (PC) can improve quality of life and survival for outpatients with advanced cancer, but there are limited population-based data on the value of inpatient PC. We assessed PC as a component of high-value care among a nationally representative sample of inpatients with metastatic cancer and identified hospitalization characteristics significantly associated with high costs.
Methods: Hospitalizations of patients 18 years and older with a primary diagnosis of metastatic cancer from the National Inpatient Sample from 2010 to 2019 were analyzed. We used multivariable mixed-effects logistic regression to assess medical services, patient demographics, and hospital characteristics associated with higher charges billed to insurance and hospital costs. Generalized linear mixed-effects models were used to determine cost savings associated with provision of PC.
Results: Among 397,691 hospitalizations from 2010 to 2019, the median charge per admission increased by 24.9%, from $44,904 in US dollars (USD) to $56,098 USD, whereas the median hospital cost remained stable at $14,300 USD. Receipt of inpatient PC was associated with significantly lower charges (odds ratio [OR], 0.62 [95% CI, 0.61 to 0.64]; P < .001) and costs (OR, 0.59 [95% CI, 0.58 to 0.61]; P < .001). Factors associated with high charges were receipt of invasive medical ventilation (P < .001) or systemic therapy (P < .001), Hispanic patients (P < .001), young age (18-49 years, P < .001), and for-profit hospitals (P < .001). PC provision was associated with a $1,310 USD (-13.6%, P < .001) reduction in costs per hospitalization compared with no PC, independent of the receipt of invasive care and age.
Conclusion: Inpatient PC is associated with reduced hospital costs for patients with metastatic cancer, irrespective of age and receipt of aggressive interventions. Integration of inpatient PC may de-escalate costs incurred through low-value inpatient interventions.